NOV 20 2012

Facility Registration Number 16-R-0029

E.4

Ninety-nine dogs assigned to Column E of this report were used in non-clinical laboratory studies to evaluate the saftey of test compounds in accordance to Food and Drug Administration requirements under Good Laboratory regulations 21 CFR 58. The animals were used on studies to detrmine the potential target organs of toxicity and no effect levels of test articles that were administered. Following multiple dosing over several days, these animals exhibited one or more clinical signs on one or more days that included diarrhea, emesis, increased salivation, tremors, and/or decreased motor activity. The dogs were not given other drugs such as analgesics or sedatives that might cause reversal of histological toxic effects of test article or induce their own inherent toxicities or drug-drug interactions. Animals were initially provided fluids, nutritional supplements or given dosing holidays to help stabilize their condition. Due to progression of clinical signs some study components were terminated early and the animals were humanely euthanized.

NOV 2 0 2012

Facility Registration Number 16-R-0029

E.9

Fourteen (14) macaque monkeys assigned to Column E of this report were used in non-clinical laboratory studies to evaluate the safety of test articles in accordance to the Food and Drug Administration requirements under Good Laboratory Practice regulations, 21 CFR 58. The animals were used on studies to determine the potential target organs of toxicity and no effect levels of test articles that were administered. Following multiple dosing over several days, the animals developed one or more clinical signs that included diarrhea, emesis, decreased motor activity, tremors, hunched posture and/or labored breathing. The animals were not given other drugs such as tranquilizers or analgesics that might cause reversal of the histological toxic effects of the test article or induce their own inherent toxicities or drug-drug interactions. The animals were initially provided nutritional supplements to help stabilize their condition. Due to progression of clinical signs the study was terminated early and the animals were humanely euthanized.

NOV 20 2012

Facility Registration Number 16-R-0029

Summary of IACUC Approved Exceptions to the Regulations and Standards

Due to unavailability of commercial pharmaceutical grade sodium pentobarbital, the IACUC approved a protocol amendment that included the use of non-pharmaceutical grade sodium pentobarbital as the anesthetic agent for terminal study procedures in dogs. As a result, non-pharmaceutical grade sodium pentobarbital was administered to one-hundred twenty-five dogs (125) dogs undergoing non-survival study procedures.

The IACUC approved a protocol that allowed housing non-human primates individually due to loss of housing partner during the study or to unavailability of compatible partners at the beginning of the study. Three (3) non-human primates were used on a study conducted under that protocol during which they were individually housed for more than 24 consecutive hours following the loss of their housing partner during the study.